Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacovigilance01:19

Pharmacovigilance

1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

14.4K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
14.4K
Subviral Agents01:29

Subviral Agents

129
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
129
Drug Regulation01:25

Drug Regulation

1.9K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.9K
Gene Therapy00:59

Gene Therapy

25.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Linerixibat: First Approval.

Drugs·2026
Same author

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

Targeted oncology·2026
Same author

Guselkumab: Pediatric First Approval.

Paediatric drugs·2026
Same author

Taletrectinib: First Approval.

Drugs·2025
Same author

Trastuzumab Rezetecan: First Approval.

Drugs·2025
Same author

Correction to: Revakinagene Taroretcel: First Approval.

Molecular diagnosis & therapy·2025

相关实验视频

Updated: Sep 18, 2025

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
07:43

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices

Published on: July 14, 2023

2.5K

雷瓦基纳基内塔罗特塞尔:第一次批准

Sheridan M Hoy1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. mdt@adis.com.

Molecular diagnosis & therapy
|June 20, 2025
PubMed
概括
此摘要是机器生成的。

雷瓦基纳基因taroretcel是一种新型基因疗法,已获批准用于二型异常性黄斑端膜切除症. 这种基于细胞的治疗为慢性视网膜疾病提供了一种新的治疗选择.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

813
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

相关实验视频

Last Updated: Sep 18, 2025

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
07:43

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices

Published on: July 14, 2023

2.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

813
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

科学领域:

  • 眼科医生 眼科 眼科
  • 基因治疗 基因治疗
  • 视网膜疾病 视网膜疾病

背景情况:

  • 异常性黄斑透视症 (MacTel) 2型是一种慢性视网膜疾病,治疗选择有限.
  • 雷瓦基纳基因taroretcel是一种封装的基于细胞的基因疗法.
  • 它提供所有基的视网膜色素上皮细胞 (RPE),这些细胞被设计成表达重组人神经营养因子 (rhCNTF).

研究的目的:

  • 要总结revakinagene taroretcel.的发展里程碑.
  • 为突出其首次获得美国FDA批准,用于治疗成年人患有2型特异性麦克泰尔病.

主要方法:

  • 雷瓦基纳基内塔罗特塞尔是作为单剂量静脉内植入物使用的.
  • 该疗法涉及封装的RPE细胞表达rhCNTF.

主要成果:

  • 在2025年3月,Revakinagene taroretcel获得了美国FDA的第一个批准,用于异常性MacTel2型.
  • 它是第一个FDA批准的治疗这种情况.
  • 该疗法已获得视网膜色素炎的孤儿药物指标和视网膜色素炎和干燥的与年龄相关的黄斑退行症的快速指标.

结论:

  • 雷瓦基纳基内塔罗特塞尔 (Revakinagene taroretcel) 是治疗慢性视网膜疾病的重大进展.
  • 批准标志着眼科基因治疗的一个里程碑.
  • 进一步的名称表明在其他视网膜疾病中的潜在应用.